Halozyme Therapeutics, Inc. (HALO)
Market Cap | 5.18B |
Revenue (ttm) | 829.25M |
Net Income (ttm) | 281.59M |
Shares Out | 127.05M |
EPS (ttm) | 2.10 |
PE Ratio | 19.22 |
Forward PE | 10.74 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 922,123 |
Open | 40.93 |
Previous Close | 40.86 |
Day's Range | 40.32 - 40.96 |
52-Week Range | 29.85 - 45.00 |
Beta | 1.25 |
Analysts | Buy |
Price Target | 51.90 (+28.56%) |
Earnings Date | May 7, 2024 |
About HALO
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) ... [Read more]
Financial Performance
In 2023, HALO's revenue was $829.25 million, an increase of 25.62% compared to the previous year's $660.12 million. Earnings were $281.59 million, an increase of 39.31%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $51.9, which is an increase of 28.56% from the latest price.
News
Halozyme to Participate in Upcoming Investor Conferences
SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present ...
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted ...
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
SAN DIEGO , Feb. 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023 financial and operating results o...
Halozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SAN DIEGO , Jan. 29, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received European Commission (EC) approval for HYQVIA® [Immune Globulin In...
Halozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis
VYVDURA® provides patients with option for self-administration SAN DIEGO , Jan. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received ap...
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SAN DIEGO , Jan. 16, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received U.S. Food and Drug Administration (FDA) approval for HYQVIA® [Imm...
Halozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types
Reduces treatment time by approximately 80% compared to standard intravenous (IV) infusion Subcutaneous (SC) injection o ffers the potential for a faster, more convenient alternative to IV infusion an...
Halozyme to Host Investor Business Forum and Long-Term Outlook Call
SAN DIEGO, Jan. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it will host an Investor Business Forum and Long-Term Outlook Call on Wednesday, J...
Halozyme to Present at Upcoming Investor Conferences
SAN DIEGO , Nov. 27, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor ...
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
VYVGART® SC Now Approved for Subcutaneous Administration, Adding to the Already Approved IV Administration SAN DIEGO , Nov. 16, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozy...
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Royalty Revenue Increased 15% YOY to Record $114.4 million Announces Acceleration into 2023 of Remaining $250M Share Repurchase through ASR GAAP Diluted EPS of $0.61 and Non-GAAP Diluted EPS of $0.75 ...
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
Acumen represents thirteenth license partner for ENHANZE ® Alzheimer's disease is a large and expanding market opportunity SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:...
Halozyme To Report Third Quarter 2023 Financial and Operating Results
SAN DIEGO , Oct. 30, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2023 financial and operating results on Monday, Nove...
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
BMS in discussions with health authorities regarding next steps for submission and approval of subcutaneous nivolumab in multiple indications SAN DIEGO , Oct. 19, 2023 /PRNewswire/ -- Halozyme Therape...
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector...
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector...
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
First subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain Tecentriq® subcutaneous formulation with ENHANZE® reduces treatment time to seven minutes compared to 30-60 ...
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Revenue Increased 45% YOY to $221.0 million; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.74 1 Royalty Revenue Increased 31% YOY to Record $111.7 million Raised 2023 Non-GAAP Diluted EPS ...
Halozyme To Report Second Quarter 2023 Financial and Operating Results
SAN DIEGO , July 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating results on Tuesday, Au...
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
SAN DIEGO , July 17, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx reported positive topline data from the ADHERE study evaluating VYVGART® H...
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
SAN DIEGO , July 13, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche's Phase 3 OCARINA II trial evaluating OCREVUS® (ocrelizumab) with ENHANZE® ...
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
VYVGART® Hytrulo is first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) SAN DIEGO , June 20, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Haloz...
Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
SAN DIEGO , June 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present at the Goldm...
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.47 1 Royalty Revenue Increased 43% YOY to $99.6 million Reiterating ...
Halozyme To Report First Quarter 2023 Financial and Operating Results
SAN DIEGO , April 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2023 financial and operating results on Tuesday, Ma...